Wockhardt is currently trading at Rs. 1275.00, up by 11.60 points or 0.92% from its previous closing of Rs. 1263.40 on the BSE.
The scrip opened at Rs. 1265.00 and has touched a high and low of Rs. 1280.00 and Rs. 1264.20 respectively. So far 18,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1325.00 on 21-Aug-2012 and a 52 week low of Rs. 251.25 on 06-Jan-2012.
Last one week high and low of the scrip stood at Rs. 1325.00 and Rs. 1234.90 respectively. The current market cap of the company is Rs. 13,953.00 crore.
The promoters holding in the company stood at 73.64% while Institutions and Non-Institutions held 8.86% and 17.32% respectively.
Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing extended-release tablets containing 2.5mg, 5mg and l0mg Felodipine, which are used in treating hypertension. Felodipine is the generic name for the brand Plendil, marketed in the United States by Astra Zeneca. The company would be launching the product immediately.
Wockhardt will be manufacturing the Felodipine API in its facility at Ankleshwar, India and the tablets of Felodipine ER at its facility in Aurangabad, India. The technology for the API and the extended-release tables were developed in-house.
According to IMS Health, the total market for this product in the US was over $66 million. Hypertension and related cardiac diseases remain a major health concern the world over.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s , the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |